<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02455726</url>
  </required_header>
  <id_info>
    <org_study_id>1601 gluta-aos</org_study_id>
    <nct_id>NCT02455726</nct_id>
  </id_info>
  <brief_title>Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease</brief_title>
  <official_title>Magnesium Oral Supplementation to Reduce Pain in Patients With Severe Peripheral Arterial Occlusive Disease: The MAG-PAPER Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Spedali Civili di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Spedali Civili di Brescia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnesium exerts analgesic effects in several animal pain models and in patients affected by
      acute postoperative pain and chronic pain of neuropathic origin. There is no evidence that
      magnesium can modulate pain in patients with peripheral arterial occlusive disease (PAOD).

      We describe the protocol of a single-center randomized double-blind clinical trial aimed at
      assessing the efficacy of oral magnesium supplementation in controlling severe pain in
      patients with advanced PAOD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Adult patients admitted to our Acute Pain Service for intractable pain will be eligible
           if they are affected by PAOD at stages III and IV of Lèriche-Fontaine classification,
           and are opioid-naïve.

        -  Patients enrolled will be randomized to the control group, treated with standard
           therapy, consisting of an oral administration of oxycodone 5 mg and pregabalin 25 mg per
           day plus placebo (fructose 10 g) twice a day for two weeks, or to the experimental
           group, treated with magnesium oxide 300 mg twice a day.

        -  Randomization will be computer-generated, with allocation concealment obtained using
           opaque, sequentially numbered and sealed envelopes. Trials participants, care providers,
           data collectors, outcome assessors and data analysts will be blinded to treatment
           allocation.

        -  Patients will be evaluated on the day of hospital admission (day 0) and on days 2, 4, 6,
           8, 12, and 14 with the following information being collected: daily oxycodone dose
           received; patient's perceived average and maximum pain using the Numerical Rating Scale
           (NRS: 0=no pain to 10=worst possible pain); pain relief using Pain Relief Scale (PRS: 0%
           no pain relief to 100% complete pain relief); characteristics of the pain, using the
           Neuropathic Pain Scale (NPS: 10 items); impact of pain on the patient's daily
           activities, using the Brief Pain Inventory (BPI; 9 items).

        -  A sample size calculation performed for the primary outcome showed that 150 patients (75
           per group) are needed to achieve 90% power to detect a minimum reduction of 30% in
           oxycodone dosage in the experimental group, after allowing for a drop-out rate of around
           20%.

        -  Ethical approval of the study protocol has been obtained from Comitato Etico Provinciale
           di Brescia, Brescia, Italy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The oxycodone dosage needed to achieve satisfactory analgesia</measure>
    <time_frame>14 days</time_frame>
    <description>Patient's satisfactory analgesia is defined as NRS ≤4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of pain relief</measure>
    <time_frame>2 days</time_frame>
    <description>The level of pain relief is measured using Pain Relief Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to satisfactory analgesia</measure>
    <time_frame>from 2 to 14 days</time_frame>
    <description>The time needed to achieve satisfactory analgesia (NRS≤4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 50% reduction of pain</measure>
    <time_frame>from 2 to 14 days</time_frame>
    <description>The time needed to achieve a reduction of pain of 50% using Pain Relief Scale(PRS = 50%)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Mg-group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard therapy plus magnesium oxide.
Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.
A rescue dose: paracetamol 1g (maximum dose 3 g per day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard therapy plus fructose.
Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.
A rescue dose: paracetamol 1g (maximum dose 3 g per day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Magnesium oxide</intervention_name>
    <description>Oral magnesium oxide 300 mg twice a day</description>
    <arm_group_label>Mg-group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fructose</intervention_name>
    <description>Oral fructose 10 g twice a day</description>
    <arm_group_label>C-group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Oxycodone hydrochloride 5 mg at 8 am</description>
    <arm_group_label>Mg-group</arm_group_label>
    <arm_group_label>C-group</arm_group_label>
    <other_name>Oxycontin, Mundipharma Pharmaceutic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Pregabalin 25 mg at 8 pm</description>
    <arm_group_label>Mg-group</arm_group_label>
    <arm_group_label>C-group</arm_group_label>
    <other_name>Lyrica, Pfizer Italia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients (18 years or above)

          -  PAOD at stages III and IV according to the Lèriche-Fontaine classification

          -  no treatment with opioids at the time of recruitment

        Exclusion Criteria:

          -  renal failure (serum creatinine ≥ 2.0 mg/dl);

          -  congestive heart failure (New York Heart Association, NYHA &gt; 3);

          -  treatment with digoxin and/or calcium channel blockers;

          -  pre-existing neuromuscular diseases;

          -  chronic diarrhea;

          -  acute limb ischemia successfully treated with interventional angiography, Fogarty
             embolectomy and/or surgical revascularization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica A Venturini, Doctor</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Monica A Venturini, Doctor</last_name>
    <email>monica.venturini@spedalicivili.brescia.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicola Latronico, Professor</last_name>
    <email>nicola.latronico@unibs.it</email>
  </overall_contact_backup>
  <reference>
    <citation>Dowell D, Kunins HV, Farley TA. Opioid analgesics--risky drugs, not risky patients. JAMA. 2013 Jun 5;309(21):2219-20. doi: 10.1001/jama.2013.5794.</citation>
    <PMID>23700072</PMID>
  </reference>
  <reference>
    <citation>Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013 Oct 19;382(9901):1329-40. doi: 10.1016/S0140-6736(13)61249-0. Epub 2013 Aug 1. Review.</citation>
    <PMID>23915883</PMID>
  </reference>
  <reference>
    <citation>Iseri LT, French JH. Magnesium: nature's physiologic calcium blocker. Am Heart J. 1984 Jul;108(1):188-93. Review.</citation>
    <PMID>6375330</PMID>
  </reference>
  <reference>
    <citation>Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl). 2005 Apr;179(1):4-29. Epub 2005 Feb 25. Review. Erratum in: Psychopharmacology (Berl). 2005 Oct;182(2):320.</citation>
    <PMID>15731895</PMID>
  </reference>
  <reference>
    <citation>Recio-Pinto E, Castillo C. Peripheral N-methyl-D-aspartate receptors as possible targets for chronic pain treatment. Techniques in Reg Anesth &amp; Pain Manag 2010;14:48-58</citation>
  </reference>
  <reference>
    <citation>Fisher K, Coderre TJ, Hagen NA. Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage. 2000 Nov;20(5):358-73. Review.</citation>
    <PMID>11068158</PMID>
  </reference>
  <reference>
    <citation>Hewitt DJ. The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain. 2000 Jun;16(2 Suppl):S73-9. Review.</citation>
    <PMID>10870744</PMID>
  </reference>
  <reference>
    <citation>De Kock MF, Lavand'homme PM. The clinical role of NMDA receptor antagonists for the treatment of postoperative pain. Best Pract Res Clin Anaesthesiol. 2007 Mar;21(1):85-98. Review.</citation>
    <PMID>17489221</PMID>
  </reference>
  <reference>
    <citation>Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg. 2003 Oct;97(4):1108-16. Review.</citation>
    <PMID>14500166</PMID>
  </reference>
  <reference>
    <citation>Nechifor M. Magnesium involvement in pain. Magnes Res. 2011 Dec;24(4):220-2. doi: 10.1684/mrh.2011.0296.</citation>
    <PMID>22061718</PMID>
  </reference>
  <reference>
    <citation>Hasanein P, Parviz M, Keshavarz M, Javanmardi K, Mansoori M, Soltani N. Oral magnesium administration prevents thermal hyperalgesia induced by diabetes in rats. Diabetes Res Clin Pract. 2006 Jul;73(1):17-22. Epub 2006 Jan 18.</citation>
    <PMID>16417942</PMID>
  </reference>
  <reference>
    <citation>Rondón LJ, Privat AM, Daulhac L, Davin N, Mazur A, Fialip J, Eschalier A, Courteix C. Magnesium attenuates chronic hypersensitivity and spinal cord NMDA receptor phosphorylation in a rat model of diabetic neuropathic pain. J Physiol. 2010 Nov 1;588(Pt 21):4205-15. doi: 10.1113/jphysiol.2010.197004.</citation>
    <PMID>20837644</PMID>
  </reference>
  <reference>
    <citation>Begon S, Pickering G, Eschalier A, Dubray C. Magnesium increases morphine analgesic effect in different experimental models of pain. Anesthesiology. 2002 Mar;96(3):627-32.</citation>
    <PMID>11873038</PMID>
  </reference>
  <reference>
    <citation>Bujalska M, Makulska-Nowak H, Gumułka SW. Magnesium ions and opioid agonists in vincristine-induced neuropathy. Pharmacol Rep. 2009 Nov-Dec;61(6):1096-104.</citation>
    <PMID>20081245</PMID>
  </reference>
  <reference>
    <citation>Ulugol A, Aslantas A, Ipci Y, Tuncer A, Hakan Karadag C, Dokmeci I. Combined systemic administration of morphine and magnesium sulfate attenuates pain-related behavior in mononeuropathic rats. Brain Res. 2002 Jul 5;943(1):101-4.</citation>
    <PMID>12088843</PMID>
  </reference>
  <reference>
    <citation>Chen Y, Zhang Y, Zhu YL, Fu PL. Efficacy and safety of an intra-operative intra-articular magnesium/ropivacaine injection for pain control following total knee arthroplasty. J Int Med Res. 2009 Nov-Dec;37(6):1733-41. Corrected and republished in: J Int Med Res. 2012;40(5):2032-40. Retraction in: J Int Med Res. 2012;40(5):2031.</citation>
    <PMID>20146871</PMID>
  </reference>
  <reference>
    <citation>Bondok RS, Abd El-Hady AM. Intra-articular magnesium is effective for postoperative analgesia in arthroscopic knee surgery. Br J Anaesth. 2006 Sep;97(3):389-92. Epub 2006 Jul 11.</citation>
    <PMID>16835255</PMID>
  </reference>
  <reference>
    <citation>Cizmeci P, Ozkose Z. Magnesium sulphate as an adjuvant to total intravenous anesthesia in septorhinoplasty: a randomized controlled study. Aesthetic Plast Surg. 2007 Mar-Apr;31(2):167-73.</citation>
    <PMID>17437152</PMID>
  </reference>
  <reference>
    <citation>Nechifor M. Magnesium in major depression. Magnes Res. 2009 Sep;22(3):163S-166S. Review.</citation>
    <PMID>19780403</PMID>
  </reference>
  <reference>
    <citation>Murck H. Ketamine, magnesium and major depression--from pharmacology to pathophysiology and back. J Psychiatr Res. 2013 Jul;47(7):955-65. doi: 10.1016/j.jpsychires.2013.02.015. Epub 2013 Mar 26. Review.</citation>
    <PMID>23541145</PMID>
  </reference>
  <reference>
    <citation>Albrecht E, Kirkham KR, Liu SS, Brull R. Peri-operative intravenous administration of magnesium sulphate and postoperative pain: a meta-analysis. Anaesthesia. 2013 Jan;68(1):79-90. doi: 10.1111/j.1365-2044.2012.07335.x. Epub 2012 Nov 1. Review.</citation>
    <PMID>23121612</PMID>
  </reference>
  <reference>
    <citation>Seyhan TO, Tugrul M, Sungur MO, Kayacan S, Telci L, Pembeci K, Akpir K. Effects of three different dose regimens of magnesium on propofol requirements, haemodynamic variables and postoperative pain relief in gynaecological surgery. Br J Anaesth. 2006 Feb;96(2):247-52. Epub 2005 Nov 25.</citation>
    <PMID>16311277</PMID>
  </reference>
  <reference>
    <citation>Ryu JH, Kang MH, Park KS, Do SH. Effects of magnesium sulphate on intraoperative anaesthetic requirements and postoperative analgesia in gynaecology patients receiving total intravenous anaesthesia. Br J Anaesth. 2008 Mar;100(3):397-403. doi: 10.1093/bja/aem407.</citation>
    <PMID>18276652</PMID>
  </reference>
  <reference>
    <citation>Tramer MR, Schneider J, Marti RA, Rifat K. Role of magnesium sulfate in postoperative analgesia. Anesthesiology. 1996 Feb;84(2):340-7.</citation>
    <PMID>8602664</PMID>
  </reference>
  <reference>
    <citation>Song JW, Lee YW, Yoon KB, Park SJ, Shim YH. Magnesium sulfate prevents remifentanil-induced postoperative hyperalgesia in patients undergoing thyroidectomy. Anesth Analg. 2011 Aug;113(2):390-7. doi: 10.1213/ANE.0b013e31821d72bc. Epub 2011 May 19.</citation>
    <PMID>21596876</PMID>
  </reference>
  <reference>
    <citation>Tugrul S, Degirmenci N, Eren SB, Dogan R, Veyseller B, Ozturan O. Analgesic effect of magnesium in post-tonsillectomy patients: a prospective randomised clinical trial. Eur Arch Otorhinolaryngol. 2015 Sep;272(9):2483-7. doi: 10.1007/s00405-014-3219-8. Epub 2014 Aug 6.</citation>
    <PMID>25097030</PMID>
  </reference>
  <reference>
    <citation>Borazan H, Kececioglu A, Okesli S, Otelcioglu S. Oral magnesium lozenge reduces postoperative sore throat: a randomized, prospective, placebo-controlled study. Anesthesiology. 2012 Sep;117(3):512-8. doi: 10.1097/ALN.0b013e3182639d5f.</citation>
    <PMID>22797283</PMID>
  </reference>
  <reference>
    <citation>Brill S, Sedgwick PM, Hamann W, Di Vadi PP. Efficacy of intravenous magnesium in neuropathic pain. Br J Anaesth. 2002 Nov;89(5):711-4.</citation>
    <PMID>12393768</PMID>
  </reference>
  <reference>
    <citation>Crosby V, Wilcock A, Corcoran R. The safety and efficacy of a single dose (500 mg or 1 g) of intravenous magnesium sulfate in neuropathic pain poorly responsive to strong opioid analgesics in patients with cancer. J Pain Symptom Manage. 2000 Jan;19(1):35-9.</citation>
    <PMID>10687324</PMID>
  </reference>
  <reference>
    <citation>Suresh S, Lozono S, Hall SC. Large-dose intravenous methotrexate-induced cutaneous toxicity: can oral magnesium oxide reduce pain? Anesth Analg. 2003 May;96(5):1413-4, table of contents.</citation>
    <PMID>12707144</PMID>
  </reference>
  <reference>
    <citation>Kroin JS, McCarthy RJ, Von Roenn N, Schwab B, Tuman KJ, Ivankovich AD. Magnesium sulfate potentiates morphine antinociception at the spinal level. Anesth Analg. 2000 Apr;90(4):913-7.</citation>
    <PMID>10735798</PMID>
  </reference>
  <reference>
    <citation>Yousef AA, Al-deeb AE. A double-blinded randomised controlled study of the value of sequential intravenous and oral magnesium therapy in patients with chronic low back pain with a neuropathic component. Anaesthesia. 2013 Mar;68(3):260-6. doi: 10.1111/anae.12107. Epub 2012 Dec 17.</citation>
    <PMID>23384256</PMID>
  </reference>
  <reference>
    <citation>Lysakowski C, Dumont L, Czarnetzki C, Tramèr MR. Magnesium as an adjuvant to postoperative analgesia: a systematic review of randomized trials. Anesth Analg. 2007 Jun;104(6):1532-9, table of contents. Review.</citation>
    <PMID>17513654</PMID>
  </reference>
  <reference>
    <citation>Pickering G, Morel V, Simen E, Cardot JM, Moustafa F, Delage N, Picard P, Eschalier S, Boulliau S, Dubray C. Oral magnesium treatment in patients with neuropathic pain: a randomized clinical trial. Magnes Res. 2011 Jun;24(2):28-35. doi: 10.1684/mrh.2011.0282.</citation>
    <PMID>21659058</PMID>
  </reference>
  <reference>
    <citation>Felsby S, Nielsen J, Arendt-Nielsen L, Jensen TS. NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Pain. 1996 Feb;64(2):283-91.</citation>
    <PMID>8740606</PMID>
  </reference>
  <reference>
    <citation>Mikkelsen S, Dirks J, Fabricius P, Petersen KL, Rowbotham MC, Dahl JB. Effect of intravenous magnesium on pain and secondary hyperalgesia associated with the heat/capsaicin sensitization model in healthy volunteers. Br J Anaesth. 2001 Jun;86(6):871-3.</citation>
    <PMID>11573598</PMID>
  </reference>
  <reference>
    <citation>Rüger LJ, Irnich D, Abahji TN, Crispin A, Hoffmann U, Lang PM. Characteristics of chronic ischemic pain in patients with peripheral arterial disease. Pain. 2008 Sep 30;139(1):201-8. doi: 10.1016/j.pain.2008.03.027. Epub 2008 May 9.</citation>
    <PMID>18472216</PMID>
  </reference>
  <reference>
    <citation>Shechter M, Bairey Merz CN, Stuehlinger HG, Slany J, Pachinger O, Rabinowitz B. Effects of oral magnesium therapy on exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease. Am J Cardiol. 2003 Mar 1;91(5):517-21.</citation>
    <PMID>12615252</PMID>
  </reference>
  <reference>
    <citation>FONTAINE R, KIENY R, GANGLOFF JM, CUNY A, SUHLER A, GONZALES I, PARAMODIAZ M. LONG-TERM RESULTS OF RESTORATIVE ARTERIAL SURGERY IN OBSTRUCTIVE DISEASES OF THE ARTERIES. J Cardiovasc Surg (Torino). 1964 Nov-Dec;5:463-72.</citation>
    <PMID>14242827</PMID>
  </reference>
  <reference>
    <citation>Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L, De Conno F. Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage. 2002 Mar;23(3):239-55. Review.</citation>
    <PMID>11888722</PMID>
  </reference>
  <reference>
    <citation>Frampton CL, Hughes-Webb P. The measurement of pain. Clin Oncol (R Coll Radiol). 2011 Aug;23(6):381-6. doi: 10.1016/j.clon.2011.04.008. Epub 2011 May 14. Review.</citation>
    <PMID>21571514</PMID>
  </reference>
  <reference>
    <citation>Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997 Feb;48(2):332-8.</citation>
    <PMID>9040716</PMID>
  </reference>
  <reference>
    <citation>Bonezzi C, Nava A, Barbieri M, Bettaglio R, Demartini L, Miotti D, Paulin L. [Validazione della versione italiana del Brief Pain Inventory nei pazienti con dolore cronico]. Minerva Anestesiol. 2002 Jul-Aug;68(7-8):607-11. Italian.</citation>
    <PMID>12244292</PMID>
  </reference>
  <reference>
    <citation>Negri E, Bettaglio R, Demartini L, Allegri M, Barbieri M, Miotti D, Paulin L, Buonocore M, Bonezzi C. [Validation of the Italian version of the &quot;Neuropathic Pain Scale&quot; and its clinical applications]. Minerva Anestesiol. 2002 Mar;68(3):95-104. Italian.</citation>
    <PMID>11981518</PMID>
  </reference>
  <reference>
    <citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.</citation>
    <PMID>3558716</PMID>
  </reference>
  <reference>
    <citation>Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994 Nov;47(11):1245-51.</citation>
    <PMID>7722560</PMID>
  </reference>
  <reference>
    <citation>Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician. 2008 Mar;11(2 Suppl):S105-20. Review.</citation>
    <PMID>18443635</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2015</study_first_submitted>
  <study_first_submitted_qc>May 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <last_update_submitted>May 25, 2015</last_update_submitted>
  <last_update_submitted_qc>May 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Spedali Civili di Brescia</investigator_affiliation>
    <investigator_full_name>Monica Aida Venturini</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Peripheral Arterial Disease</keyword>
  <keyword>Magnesium Oxide</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Magnesium Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

